IMGN
Immunogen Inc
stock NASDAQ

The recent Market Action is telling all who don't know or who aren't sure, - Gps is 100% for Sure Getting FDA Approval and that SLS is worth F Ton More than what shorts sold it Down for - What is GPS TRULY WORTH?
Incoming Phase 3 Results for GPS Immunotherapy are offering a true Once in a Lifetime Investment Opportunity.
$.64b Manipulated Market Cap worth $40B to Big Pharma the Instant the Phase 3 Results are Announced.
**- The Value of a Positive Phase 3 Result exceeds $40B, more than 77x the current manipulated $.6b mcap. SLS Share Price will continue climbing until the P3 Results are released, and then it Launches.**
\- Big Pharma's Pay 4X Revenue Multiples in buyouts.
\- 12,500 AML CR2/CR3 Patients Each Year\* - current P3 Setting. SLS published est\* rev per patient of $280K /year. ​\*\*- $3.5B Year 1 TAM\*\*
Currently 5-7,000 AML CR2 Patients Who Also Will Be Immediately Eligible for Gps Immunotherapy right out of the Gate upon approval: 5,000 \* $280k = $1.4B
**Year 1 Total Addressable Market $4.9B** for Just for AML CR2/3 - the Setting for the Phase 3 Trial.
AND THEN COMPOUND IT - Infinite Dosing to Until Relapse
\- Year 1 Rev $280K Per Patient / 15 Doses - Year 2 Rev $112K Per Patient / 6 Doses
\- Year 3+ Rev $70K Per Patient / 4 Doses
the Ad Infinitum Dosing Regime Doubles the Total Addressable Market for AML CR2 CR3
Then Add AML CR1/ Post ASCT - 5X the SIZE of CR2/3
Esp w VIALE-M CR1 Trial Failing and VIALE-T P/Asct Failing.
**You absolutely Know Big Pharma Will be Adding AML CR1 Patient and AML Post Asct Patient Populations to the Potential Revenue Calculations.**Gps will be Effective in over 20 different cancer settings that harbour WT1 +. GPs has already proven effective in Mesothelioma and Platinum Resistant Ovarian Cancer settings, achieving better Phase 2 Combination trial Results with Keytruda $MRK - MOS of 18.4 months - than, Elahere $IMGN 16.4 Months, which earned FDA Approval and was bought by $abbv for $10.1B - this is just 1 comp worth $10B.
\* Sources available upon request
\--
ABVX was a $5 and change Equity prior to releasing its Phase 3 Trial Results - it launched on the P3 announcement - T1 Trading Halt and a Gap UP opening at $60 and it Kept on Climbing to a high of $145.
\- buyout expected/

The recent Market Action is telling all who don't know or who aren't sure, - Gps is 100% for Sure Getting FDA Approval and that SLS is worth F Ton More than what shorts sold it Down for - What is GPS TRULY WORTH?
Incoming Phase 3 Results for GPS Immunotherapy are offering a true Once in a Lifetime Investment Opportunity.
$.64b Manipulated Market Cap worth $40B to Big Pharma the Instant the Phase 3 Results are Announced.
**- The Value of a Positive Phase 3 Result exceeds $40B, more than 77x the current manipulated $.6b mcap. SLS Share Price will continue climbing until the P3 Results are released, and then it Launches.**
\- Big Pharma's Pay 4X Revenue Multiples in buyouts.
\- 12,500 AML CR2/CR3 Patients Each Year\* - current P3 Setting. SLS published est\* rev per patient of $280K /year. ​\*\*- $3.5B Year 1 TAM\*\*
Currently 5-7,000 AML CR2 Patients Who Also Will Be Immediately Eligible for Gps Immunotherapy right out of the Gate upon approval: 5,000 \* $280k = $1.4B
**Year 1 Total Addressable Market $4.9B** for Just for AML CR2/3 - the Setting for the Phase 3 Trial.
AND THEN COMPOUND IT - Infinite Dosing to Until Relapse
\- Year 1 Rev $280K Per Patient / 15 Doses - Year 2 Rev $112K Per Patient / 6 Doses
\- Year 3+ Rev $70K Per Patient / 4 Doses
the Ad Infinitum Dosing Regime Doubles the Total Addressable Market for AML CR2 CR3
Then Add AML CR1/ Post ASCT - 5X the SIZE of CR2/3
Esp w VIALE-M CR1 Trial Failing and VIALE-T P/Asct Failing.
**You absolutely Know Big Pharma Will be Adding AML CR1 Patient and AML Post Asct Patient Populations to the Potential Revenue Calculations.**Gps will be Effective in over 20 different cancer settings that harbour WT1 +. GPs has already proven effective in Mesothelioma and Platinum Resistant Ovarian Cancer settings, achieving better Phase 2 Combination trial Results with Keytruda $MRK - MOS of 18.4 months - than, Elahere $IMGN 16.4 Months, which earned FDA Approval and was bought by $abbv for $10.1B - this is just 1 comp worth $10B.
\* Sources available upon request
\--
ABVX was a $5 and change Equity prior to releasing its Phase 3 Trial Results - it launched on the P3 announcement - T1 Trading Halt and a Gap UP opening at $60 and it Kept on Climbing to a high of $145.
\- buyout expected/